HAS1 and glioblastoma: With encapsulating an MMPs inhibitor (SB-3CT) and HAS inhibitor (4-MU) separately within the hydrogel, they showed that inhibiting both MMPs and HA synthases genes (HAS) significantly suppressed GBM cell motility and migration, while cell elongation was also decreased.